| Cancer Associated Retinopathy | |
|---|---|
| Specialty | Ophthalmology, optometry |
| Complications | Blindness [1] |
| Diagnostic method | Eye examination |
| Differential diagnosis | Retinitis pigmentosa |
| Treatment | Immunosuppression |
Cancer Associated Retinopathy (CAR) also known as Carcinoma Associated Retinopathy is an immune-mediated disease affecting the retina of the eye. It is a paraneoplastic type autoimmune retinopathy associated with cancer that can cause blindness. It can be seen in association with various types of cancers. It can be treated with a combination of chemotherapy and immunosuppression.
Pathophysiology
It is a paraneoplastic type of autoimmune retinopathy. [2] It may be seen in association with various cancers including non-small cell lung cancer, breast cancer, gynacological cancers, tumors of the hematopoietic and lymphoid tissues, basal cell carcinoma, colon cancer, kidney cancer, prostate cancer and pancreatic cancer. [1]
CAR results from the interaction between retinal antigen expression in cancer tissues and their systemic immune response. These antigens trigger an autoimmune response within the host to form antibodies that cross-react with the retinal antigen. This ultimately leads to retinal degeneration and apoptosis. Recoverin is the most common antigen associated with CAR. [3]
Prevalence
The prevalence of CAR among cancer patients is thought to be 10%–15%. [4]
Signs and symptoms
Patients may complain loss of vision, black spots in the field of vision ( scotoma), night blindness, prolonged glare after light exposure, prolonged dark adaptation and defects in colour vision (dyschromatopsia). [5] Major signs include circulating anti-retinal antibodies along with loss of the outer retinal layer including the ellipsoid layer and photoreceptor cells, abnormalities in ERG, fundus autofluorescence and visual field defectss. [5]
Diagnosis
CAR is suspected in cancer patients who present with unexplained visual loss, scotomas and an abnormal ERG. [6] Antiretinal antibodies can be detected using Western blot test, immunohistochemistry test or ELISA testing. But the diagnosis is challenging as the signs and symptoms overlaps with many other diseases affecting the retina. [7]
Treatment
Long-term systemic Immunosuppressive therapy is the main treatment of cancer-associated retinopathy. [5] It can be treated with a combination of chemotherapy and immunosuppression. [2] Although tumor removal and cancer regression may result in a decrease in circulating autoantibodies, this does not influence CAR progression. [8]
Systematic immunosuppressive medications used in the treatment include corticosteroids, cyclosporin, azathioprine and alemtuzumab. [5] Intravenous immunoglobulin injections have several advantages including neutralization of autoantibodies. [5] Various monoclonal antibodies are also used to treat CAR. [1]
History
In 1976, cancer-related vision loss and photoreceptor dysfunction were first described by Sawyer et al. [2]
References
- ^ a b c Singh, Dheerendra; Tripathy, Koushik (2022), "Cancer Associated Retinopathy", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 35201711, archived from the original on 2023-11-07, retrieved 2023-02-16
- ^ a b c Grange, Landon; Dalal, Monica; Nussenblatt, Robert B.; Sen, H. Nida (February 2014). "Autoimmune Retinopathy". American Journal of Ophthalmology. 157 (2): 266–272.e1. doi: 10.1016/j.ajo.2013.09.019. ISSN 0002-9394. PMC 3946999. PMID 24315290.
- ^ Dy, Irene; Chintapatla, Rangaswamy; Preeshagul, Isabel; Becker, Daniel (2013-11-01). "Treatment of Cancer-Associated Retinopathy With Rituximab". Journal of the National Comprehensive Cancer Network. 11 (11): 1320–1324. doi: 10.6004/jnccn.2013.0156. ISSN 1540-1405. PMID 24225966. Archived from the original on 2023-02-16. Retrieved 2023-02-16.
- ^ Dimitriou, Eleni; Chatzirallis, Alexandros; Katopodis, Sokratis; Theodossiadis, George; Theodossiadis, Panagiotis; Chatziralli, Irini (2021-05-01). "Cancer-associated retinopathy 4 years after surgery for ovarian cancer". Oman Journal of Ophthalmology. 14 (2): 108–111. doi: 10.4103/ojo.ojo_352_20. ISSN 0974-620X. PMC 8300284. PMID 34345145.
- ^ a b c d e "Cancer Associated Retinopathy - EyeWiki". eyewiki.aao.org. Archived from the original on 2023-02-16. Retrieved 2023-02-16.
- ^ Goetgebuer, Griet; Kestelyn-Stevens, A.-M.; Laey, J.; Kestelyn, P.; Leroy, B. (2007). "Cancer-associated retinopathy (CAR) with electronegative ERG: a case report". Documenta Ophthalmologica. 116 (1): 49–55. doi: 10.1007/s10633-007-9074-9. PMID 17721792. S2CID 9253958.
- ^ "Diagnosis and Management of Autoimmune Retinopathy". American Academy of Ophthalmology. 2017-09-01. Archived from the original on 2023-02-16. Retrieved 2023-02-16.
- ^ "Cancer associated retinopathy". Eye News. Archived from the original on 2023-02-16. Retrieved 2023-02-16.
| Cancer Associated Retinopathy | |
|---|---|
| Specialty | Ophthalmology, optometry |
| Complications | Blindness [1] |
| Diagnostic method | Eye examination |
| Differential diagnosis | Retinitis pigmentosa |
| Treatment | Immunosuppression |
Cancer Associated Retinopathy (CAR) also known as Carcinoma Associated Retinopathy is an immune-mediated disease affecting the retina of the eye. It is a paraneoplastic type autoimmune retinopathy associated with cancer that can cause blindness. It can be seen in association with various types of cancers. It can be treated with a combination of chemotherapy and immunosuppression.
Pathophysiology
It is a paraneoplastic type of autoimmune retinopathy. [2] It may be seen in association with various cancers including non-small cell lung cancer, breast cancer, gynacological cancers, tumors of the hematopoietic and lymphoid tissues, basal cell carcinoma, colon cancer, kidney cancer, prostate cancer and pancreatic cancer. [1]
CAR results from the interaction between retinal antigen expression in cancer tissues and their systemic immune response. These antigens trigger an autoimmune response within the host to form antibodies that cross-react with the retinal antigen. This ultimately leads to retinal degeneration and apoptosis. Recoverin is the most common antigen associated with CAR. [3]
Prevalence
The prevalence of CAR among cancer patients is thought to be 10%–15%. [4]
Signs and symptoms
Patients may complain loss of vision, black spots in the field of vision ( scotoma), night blindness, prolonged glare after light exposure, prolonged dark adaptation and defects in colour vision (dyschromatopsia). [5] Major signs include circulating anti-retinal antibodies along with loss of the outer retinal layer including the ellipsoid layer and photoreceptor cells, abnormalities in ERG, fundus autofluorescence and visual field defectss. [5]
Diagnosis
CAR is suspected in cancer patients who present with unexplained visual loss, scotomas and an abnormal ERG. [6] Antiretinal antibodies can be detected using Western blot test, immunohistochemistry test or ELISA testing. But the diagnosis is challenging as the signs and symptoms overlaps with many other diseases affecting the retina. [7]
Treatment
Long-term systemic Immunosuppressive therapy is the main treatment of cancer-associated retinopathy. [5] It can be treated with a combination of chemotherapy and immunosuppression. [2] Although tumor removal and cancer regression may result in a decrease in circulating autoantibodies, this does not influence CAR progression. [8]
Systematic immunosuppressive medications used in the treatment include corticosteroids, cyclosporin, azathioprine and alemtuzumab. [5] Intravenous immunoglobulin injections have several advantages including neutralization of autoantibodies. [5] Various monoclonal antibodies are also used to treat CAR. [1]
History
In 1976, cancer-related vision loss and photoreceptor dysfunction were first described by Sawyer et al. [2]
References
- ^ a b c Singh, Dheerendra; Tripathy, Koushik (2022), "Cancer Associated Retinopathy", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 35201711, archived from the original on 2023-11-07, retrieved 2023-02-16
- ^ a b c Grange, Landon; Dalal, Monica; Nussenblatt, Robert B.; Sen, H. Nida (February 2014). "Autoimmune Retinopathy". American Journal of Ophthalmology. 157 (2): 266–272.e1. doi: 10.1016/j.ajo.2013.09.019. ISSN 0002-9394. PMC 3946999. PMID 24315290.
- ^ Dy, Irene; Chintapatla, Rangaswamy; Preeshagul, Isabel; Becker, Daniel (2013-11-01). "Treatment of Cancer-Associated Retinopathy With Rituximab". Journal of the National Comprehensive Cancer Network. 11 (11): 1320–1324. doi: 10.6004/jnccn.2013.0156. ISSN 1540-1405. PMID 24225966. Archived from the original on 2023-02-16. Retrieved 2023-02-16.
- ^ Dimitriou, Eleni; Chatzirallis, Alexandros; Katopodis, Sokratis; Theodossiadis, George; Theodossiadis, Panagiotis; Chatziralli, Irini (2021-05-01). "Cancer-associated retinopathy 4 years after surgery for ovarian cancer". Oman Journal of Ophthalmology. 14 (2): 108–111. doi: 10.4103/ojo.ojo_352_20. ISSN 0974-620X. PMC 8300284. PMID 34345145.
- ^ a b c d e "Cancer Associated Retinopathy - EyeWiki". eyewiki.aao.org. Archived from the original on 2023-02-16. Retrieved 2023-02-16.
- ^ Goetgebuer, Griet; Kestelyn-Stevens, A.-M.; Laey, J.; Kestelyn, P.; Leroy, B. (2007). "Cancer-associated retinopathy (CAR) with electronegative ERG: a case report". Documenta Ophthalmologica. 116 (1): 49–55. doi: 10.1007/s10633-007-9074-9. PMID 17721792. S2CID 9253958.
- ^ "Diagnosis and Management of Autoimmune Retinopathy". American Academy of Ophthalmology. 2017-09-01. Archived from the original on 2023-02-16. Retrieved 2023-02-16.
- ^ "Cancer associated retinopathy". Eye News. Archived from the original on 2023-02-16. Retrieved 2023-02-16.